

Special Issue

The Outcome of Radiation Therapy in Breast Cancer

Message from the Guest Editor

In 2020, breast cancer became the most common cancers in women worldwide, accounting for 11.7% of female cancer cases. Radiation therapy is an important component in the multimodal management of breast cancer, including early-stage and locally advanced breast cancers, as well as metastatic cases. Breast cancer radiation therapy has seen significant advancements over the past 20 years. Radiation therapy uses high-energy radiation to kill cancer cells by damaging their DNA. With improved life expectancy, the increasingly complex challenge is to maintain quality of life. This requires the identification of what are the foremost clinically meaningful effects of therapeutic breast radiation, taking into account the changing landscape of chemo-, endocrine and immunotherapy with their potential interactions, in order to reach the optimal balance between tumor control and sparing normal tissues and organs. The Special Issue aims to present a collection of original research articles and reviews that explore the vast domain of the outcomes of radiation therapy in breast cancer.

Guest Editor

Dr. Vincent Vinh-Hung

Department of Radiotherapy, Institut Bergonié, 33000 Bordeaux, France

Deadline for manuscript submissions

closed (10 January 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/174115

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)